Prostate care at RPCI integrates surgical, radiation, and medical oncology specialists tailoring personalized treatment plans. They work in concert
with your primary care physician, ensuring continuity of care from diagnosis through long-term follow-up.
Strong connections between research and clinical care is evident in medical advances and technologies developed at RPCI:
Robot-assisted surgery and other minimally invasive techniques are now used to perform 99% of prostate cancer surgeries at Roswell Park.
Prostate Specific Antigen (PSA) test detects prostate cancer 5–10 years earlier than previous screening methods.
LNCaP, the most studied prostate cancer cell line in the world.
Photodynamic therapy (PDT) uses lasers to activate photosensitive drugs to kill cancer cells.
RPCI is a member of the National Comprehensive Cancer Network (NCCN), an alliance of the nation’s top cancer centers, which develops the most widely used guidelines for cancer early detection and treatment. RPCI physicians who are members of the NCCN Prostate Cancer Guidelines Committee are:
James Mohler, MD, Chair of Urology and Chair of the Prostate Cancer Treatment Guideline Committee.
Michael Kuettel, MD, PhD, MBA, Chair of Radiation Medicine and co-author of the original Prostate Cancer Treatment Guideline (1999).
Robert Huben, MD, the Robert P. Huben Professor of Urology and co-author of the original Prostate Cancer Treatment Guideline (1999).
Informational Videos About Prostate Cancer from Roswell Park Cancer Institute
Value of Second Opinion and Treatment Options
Prostate Survivor - Richard
The Roswell Park Cancer Institute Prostate Cancer Team
Michael Kuettel, MD, PhD, MBA
David Cho, MD
Anurag Singh, MD
Ellis Levine, MD
Donald Trump, MD, FACP
Roberto Pili, MD
Saby George, MD
James Mohler, MD
Khurshid Guru, MD
Robert Huben, MD
Thomas Schwaab, MD, PhD
Willie Underwood III, MD, MPH, MSci
Active Prostate Cancer Clinical Trials at Roswell Park Cancer Institute:
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer